Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5177519
Max Phase: Preclinical
Molecular Formula: C27H38ClF2N5OS
Molecular Weight: 554.15
Associated Items:
ID: ALA5177519
Max Phase: Preclinical
Molecular Formula: C27H38ClF2N5OS
Molecular Weight: 554.15
Associated Items:
Canonical SMILES: Cc1nnc(C(C)C)n1[C@@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccsc1Cl
Standard InChI: InChI=1S/C27H38ClF2N5OS/c1-16(2)25-33-32-17(3)35(25)21-14-19-4-5-20(15-21)34(19)12-8-23(22-9-13-37-24(22)28)31-26(36)18-6-10-27(29,30)11-7-18/h9,13,16,18-21,23H,4-8,10-12,14-15H2,1-3H3,(H,31,36)/t19-,20+,21-,23-/m0/s1
Standard InChI Key: AZNVXQZJVHWBAJ-KGSLCBSSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 554.15 | Molecular Weight (Monoisotopic): 553.2454 | AlogP: 6.67 | #Rotatable Bonds: 8 |
Polar Surface Area: 63.05 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.30 | CX Basic pKa: 8.34 | CX LogP: 4.18 | CX LogD: 3.19 |
Aromatic Rings: 2 | Heavy Atoms: 37 | QED Weighted: 0.40 | Np Likeness Score: -1.06 |
1. Xie X, Zheng YG, Chen H, Li J, Luo RH, Chen L, Zheng CB, Zhang S, Peng P, Ma D, Yang LM, Zheng YT, Liu H, Wang J.. (2022) Structure-Based Design of Tropane Derivatives as a Novel Series of CCR5 Antagonists with Broad-Spectrum Anti-HIV-1 Activities and Improved Oral Bioavailability., 65 (24.0): [PMID:36472561] [10.1021/acs.jmedchem.2c01383] |
Source(1):